Viking Therapeutics 2026 shareholder votes detailed

Viking Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Viking Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of the 115,893,943 common shares outstanding as of March 20, 2026, 80,089,532 shares were represented, about 69.1% of shares entitled to vote, establishing a quorum.

Stockholders elected Class II directors J. Matthew Singleton and S. Kathryn Rouan, Ph.D., to serve until the 2029 annual meeting or until their successors are elected and qualified. They also ratified the selection of CBIZ CPAs P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026.

On an advisory basis, stockholders approved the compensation of the company’s named executive officers as disclosed in the proxy statement. These outcomes confirm continuity in Viking’s board composition, auditor relationship, and executive pay program.

8-K Event Classification

2 items: 5.07, 9.01

2 items

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Shares outstanding: 115,893,943 shares Shares represented: 80,089,532 shares Quorum percentage: 69.1% +5 more

8 metrics

Shares outstanding 115,893,943 shares Common stock outstanding as of March 20, 2026

Shares represented 80,089,532 shares Shares present or by proxy at 2026 Annual Meeting

Quorum percentage 69.1% Portion of outstanding shares entitled to vote represented

Auditor ratification for votes 78,368,957 shares Votes for CBIZ CPAs P.C. as auditor for 2026

Auditor ratification against votes 1,241,969 shares Votes against CBIZ CPAs P.C. as auditor for 2026

Say-on-pay for votes 30,045,938 shares Votes approving executive compensation on advisory basis

Say-on-pay against votes 12,763,135 shares Votes against executive compensation on advisory basis

Broker non-votes on say-on-pay 36,879,063 shares Broker non-votes for advisory compensation proposal

Key Terms

Annual Meeting of Stockholders, broker non-votes, independent registered public accounting firm, advisory basis, +1 more

5 terms

Annual Meeting of Stockholders financial

"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."

broker non-votes financial

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

advisory basis financial

"To approve, on an advisory basis, the compensation of the Company’s named executive officers"

named executive officers financial

"the compensation of the Company’s named executive officers as disclosed in the Proxy Statement"

Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was the quorum at Viking Therapeutics (VKTX) 2026 annual meeting?

Viking Therapeutics reached a quorum with 80,089,532 shares represented, about 69.1% of eligible shares. This was based on 115,893,943 common shares outstanding as of March 20, 2026, the record date for the 2026 Annual Meeting of Stockholders.

Which directors were elected at Viking Therapeutics (VKTX) 2026 annual meeting?

Stockholders elected J. Matthew Singleton and S. Kathryn Rouan, Ph.D., as Class II directors. They will serve until the 2029 annual meeting of stockholders, or until their respective successors are duly elected and qualified, maintaining board continuity for Viking Therapeutics.

Did Viking Therapeutics (VKTX) stockholders ratify the company’s independent auditor?

Yes, stockholders ratified CBIZ CPAs P.C. as independent registered public accounting firm for 2026. The vote was 78,368,957 shares for, 1,241,969 against, and 478,606 abstentions, confirming support for the company’s external audit relationship.

How did Viking Therapeutics (VKTX) stockholders vote on executive compensation in 2026?

Stockholders approved, on an advisory basis, the compensation of named executive officers. The vote totaled 30,045,938 shares for, 12,763,135 against, 401,396 abstentions, and 36,879,063 broker non-votes, indicating majority support for the disclosed pay program.

What key proposals were considered at Viking Therapeutics (VKTX) 2026 annual meeting?

Three proposals were considered: electing two Class II directors, ratifying the independent auditor, and approving executive compensation on an advisory basis. Stockholders approved all three, covering governance, audit oversight, and the company’s compensation program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/26/2026 - 04:48 PM EDT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): May 19, 2026

    

Viking Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-37355	46-1073877
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9920 Pacific Heights Blvd, Suite 500
San Diego, California		92121
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 858 704-4660

    

     Viking Therapeutics, Inc.

    

Pacific Heights Blvd, Suite 350

    

     San Diego, California 92121

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.00001 per share	VKTX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 19, 2026, Viking Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 115,893,943 shares of the Company’s common stock outstanding as of March 20, 2026, the record date for the Annual Meeting, 80,089,532 shares were represented at the Annual Meeting virtually or by proxy, constituting approximately 69.1% of the outstanding shares entitled to vote and constituting a quorum for the transaction of business.

At the Annual Meeting, the Company’s stockholders considered three proposals, each of which is described in more detail in the Company’s revised definitive proxy statement filed with the Securities and Exchange Commission on April 1, 2026 (the “Proxy Statement”).

Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal.

Proposal No. 1. To elect the following nominees as Class II directors to serve until the Company’s 2029 annual meeting of stockholders or until such director’s respective successor is duly elected and qualified:


Director Nominee	Votes For	Votes Withheld	Broker Non-Votes
J. Matthew Singleton	28,648,459	14,562,012	36,879,061
S. Kathryn Rouan, Ph.D.	21,960,203	21,250,268	36,879,061

As a result, the Company’s stockholders voted to elect J. Matthew Singleton and S. Kathryn Rouan, Ph.D., as Class II directors to serve until the Company’s 2029 annual meeting of stockholders or until such director’s respective successor is duly elected and qualified.

Proposal No. 2. To ratify the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026:


Votes For	Votes Against	Abstentions
78,368,957	1,241,969	478,606

As a result, the Company’s stockholders voted to ratify the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026.

Proposal No. 3. To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement:


Votes For	Votes Against	Abstentions	Broker Non-Votes
30,045,938	12,763,135	401,396	36,879,063

As a result, the Company’s stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No		Description
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			VIKING THERAPEUTICS, INC.

Date:	May 26, 2026	By:	/s/ Brian Lian, Ph.D.
			Brian Lian, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document